Biotronik's rate-adaptive pacemakers get US clearance:
This article was originally published in Clinica
Biotronik has obtained FDA approval to launch its Actros family of rate-adaptive single and dual chamber pacemakers. The 6mm wide device can switch modes within one cycle to correct atrial arrhythmia, and uses 50% less power than earlier devices, says the company.
You may also be interested in...
The US is to ship only half of doses for Pfizer, Moderna COVID-19 vaccines in the first instance, while Rhizen Pharmaceuticals starts a Phase I trial of a DHODH inhibitor.
Given its ever-growing role as a critical component of the global biopharma industry, you can’t afford not to be up to speed on Asia. This biweekly selection of insights from our experienced on-the-ground team will help.
Becton Dickinson will spend $1.2bn over the next four years to improve its drug-delivery device manufacturing capabilities. See what Eric Borin, president of BD, said about it here.